Treffer: Fever Inspiration: Precision Engineering for Safe and Systemic Immunotherapy.
Title:
Fever Inspiration: Precision Engineering for Safe and Systemic Immunotherapy.
Authors:
Li Y; Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration, Ministry of Education, Tongji Hospital, Department of Pharmacy, School of Medicine, Tongji University, Shanghai, 200065, China., Man F; Shanghai Skin Disease Hospital, The Institute for Biomedical Engineering and Nano Science (iNANO), School of Medicine, Tongji University, Shanghai, 200331, China., Cheng J; Shanghai Skin Disease Hospital, The Institute for Biomedical Engineering and Nano Science (iNANO), School of Medicine, Tongji University, Shanghai, 200331, China., Chen L; Shanghai Skin Disease Hospital, The Institute for Biomedical Engineering and Nano Science (iNANO), School of Medicine, Tongji University, Shanghai, 200331, China., Li Y; Shanghai Skin Disease Hospital, The Institute for Biomedical Engineering and Nano Science (iNANO), School of Medicine, Tongji University, Shanghai, 200331, China., Dong H; Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration, Ministry of Education, Tongji Hospital, Department of Pharmacy, School of Medicine, Tongji University, Shanghai, 200065, China.
Source:
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2026 Jan; Vol. 13 (1), pp. e13566. Date of Electronic Publication: 2025 Nov 26.
Publication Type:
Journal Article; Review
Language:
English
Journal Info:
Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844 (Electronic) Linking ISSN: 21983844 NLM ISO Abbreviation: Adv Sci (Weinh) Subsets: MEDLINE
Imprint Name(s):
Original Publication: Weinheim : WILEY-VCH, [2014]-
MeSH Terms:
References:
Clin Infect Dis. 2000 Oct;31 Suppl 5:S178-84. (PMID: 11113021)
ACS Nano. 2023 Oct 10;17(19):19242-19253. (PMID: 37781935)
Chem Soc Rev. 2019 Apr 1;48(7):2053-2108. (PMID: 30259015)
DNA Cell Biol. 2023 Mar;42(3):107-112. (PMID: 36720071)
Nat Commun. 2016 Feb 04;7:10437. (PMID: 26842674)
Open Forum Infect Dis. 2020 May 02;7(5):ofaa132. (PMID: 32462043)
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66. (PMID: 11602373)
Adv Sci (Weinh). 2025 Jun;12(22):e2417625. (PMID: 40279550)
Adv Sci (Weinh). 2019 Sep 12;6(22):1901690. (PMID: 31763151)
Small. 2021 Apr;17(14):e2005241. (PMID: 33734595)
Biomedicines. 2024 Sep 23;12(9):. (PMID: 39335671)
Nano Lett. 2019 Aug 14;19(8):5277-5286. (PMID: 31331173)
J Leukoc Biol. 2011 Nov;90(5):951-62. (PMID: 21873456)
J Am Chem Soc. 2018 Feb 14;140(6):2165-2178. (PMID: 29376345)
J Physiol. 2024 May;602(10):2227-2251. (PMID: 38690610)
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22357-22366. (PMID: 32839313)
Int J Nanomedicine. 2024 Apr 29;19:3827-3846. (PMID: 38708180)
J Lipid Res. 2024 Sep;65(9):100617. (PMID: 39128824)
Adv Mater. 2023 Nov;35(48):e2303149. (PMID: 37691545)
Front Cell Dev Biol. 2023 May 25;11:1186050. (PMID: 37305674)
Small Methods. 2023 May;7(5):e2300354. (PMID: 37191336)
Chest. 2004 Nov;126(5):1645-55. (PMID: 15539739)
J Leukoc Biol. 2007 Nov;82(5):1322-31. (PMID: 17711975)
J Immunol. 1998 Jan 15;160(2):961-9. (PMID: 9551935)
Sci Rep. 2021 Mar 22;11(1):6531. (PMID: 33753764)
Am J Med Sci. 2024 Aug;368(2):85-89. (PMID: 38795968)
EMBO Mol Med. 2012 Jul;4(7):617-32. (PMID: 22367739)
Anticancer Res. 2004 Sep-Oct;24(5C):3295-301. (PMID: 15515424)
Int J Hyperthermia. 2013 Aug;29(5):423-35. (PMID: 23863046)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
Neuroscientist. 2018 Aug;24(4):381-399. (PMID: 29557255)
Pediatr Blood Cancer. 2005 Jun 15;44(7):679-81. (PMID: 15700247)
Blood. 2001 May 1;97(9):2727-33. (PMID: 11313264)
J Neurooncol. 2006 May;78(1):7-14. (PMID: 16314937)
J Leukoc Biol. 2007 May;81(5):1179-87. (PMID: 17311933)
Cancer Immunol Immunother. 2002 Dec;51(11-12):603-13. (PMID: 12439605)
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2408969121. (PMID: 39680767)
Nat Commun. 2021 Feb 2;12(1):742. (PMID: 33531498)
Crit Care. 2011;15(3):222. (PMID: 21672276)
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. (PMID: 33608497)
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):. (PMID: 34161266)
Compr Physiol. 2013 Apr;3(2):785-97. (PMID: 23720329)
Metabolites. 2023 Mar 22;13(3):. (PMID: 36984901)
Semin Cancer Biol. 2022 Dec;87:17-31. (PMID: 36354098)
Nucleic Acids Res. 2016 Apr 7;44(6):2888-97. (PMID: 26825461)
Nat Commun. 2019 Oct 25;10(1):4871. (PMID: 31653838)
Clin Transl Med. 2023 May;13(5):e1256. (PMID: 37218972)
Annu Rev Pathol. 2018 Jan 24;13:395-412. (PMID: 29414248)
Res Microbiol. 1994 May;145(4):269-72. (PMID: 7997640)
Nat Rev Neurosci. 2003 Jul;4(7):529-39. (PMID: 12838328)
Cell Mol Immunol. 2016 May;13(3):316-27. (PMID: 26908374)
Cancer Cell. 2021 Sep 13;39(9):1167-1168. (PMID: 34388378)
World J Clin Cases. 2021 Jan 16;9(2):296-307. (PMID: 33521098)
Lancet. 1982 May 8;1(8280):1079-80. (PMID: 6122886)
Immunol Lett. 2005 Apr 15;98(1):153-9. (PMID: 15790521)
Transl Oncol. 2018 Apr;11(2):330-337. (PMID: 29425952)
Small. 2019 Mar;15(13):e1900205. (PMID: 30828968)
Kidney Res Clin Pract. 2015 Dec;34(4):194-200. (PMID: 26779421)
Nature. 2022 Jun;606(7916):937-944. (PMID: 35676482)
J Comp Neurol. 2004 Apr 19;472(1):113-29. (PMID: 15024756)
Pharmacol Ther. 2006 Jul;111(1):194-223. (PMID: 16460809)
Immunity. 2020 Feb 18;52(2):328-341.e5. (PMID: 32049050)
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1865-70. (PMID: 15684048)
Adv Sci (Weinh). 2020 Jul 17;7(17):2000863. (PMID: 32995121)
Sci Immunol. 2024 Sep 20;9(99):eadp3475. (PMID: 39303018)
Endocrinology. 2012 Oct;153(10):4849-61. (PMID: 22872578)
J Immunol. 2005 Mar 15;174(6):3676-85. (PMID: 15749906)
Biomark Res. 2023 Mar 9;11(1):28. (PMID: 36890557)
Clin Cancer Res. 2001 Jan;7(1):215-9. (PMID: 11205912)
J Neurosci. 2017 May 10;37(19):5035-5044. (PMID: 28438967)
Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):245-256. (PMID: 38769827)
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R332-R339. (PMID: 15802558)
J Control Release. 2015 Apr 28;204:85-97. (PMID: 25744825)
Adv Sci (Weinh). 2025 Jan;12(2):e2406328. (PMID: 39574346)
Small. 2024 Feb;20(7):e2305426. (PMID: 37803412)
Nat Rev Drug Discov. 2022 Jan;21(1):41-59. (PMID: 34526696)
Intractable Rare Dis Res. 2016 May;5(2):97-102. (PMID: 27195192)
Neurology. 1997 Mar;48(3):768-73. (PMID: 9065563)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Nat Commun. 2023 Nov 4;14(1):7107. (PMID: 37925510)
Signal Transduct Target Ther. 2021 Feb 26;6(1):94. (PMID: 33637672)
ACS Nano. 2025 Apr 08;19(13):12982-12995. (PMID: 40138545)
N Engl J Med. 2020 Dec 3;383(23):2255-2273. (PMID: 33264547)
Adv Sci (Weinh). 2018 Mar 25;5(6):1700805. (PMID: 29938166)
Adv Mater. 2014 Dec 23;26(48):8154-62. (PMID: 25331930)
Acta Oncol. 2013 Feb;52(2):455-7. (PMID: 22934556)
Nat Neurosci. 2007 Sep;10(9):1131-3. (PMID: 17676060)
Int J Mol Sci. 2024 Apr 10;25(8):. (PMID: 38673794)
J Immunol. 2009 Jun 15;182(12):7451-8. (PMID: 19494268)
Ann N Y Acad Sci. 1998 Sep 29;856:224-233. (PMID: 9917881)
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2030-2037. (PMID: 36084325)
J Am Chem Soc. 2025 Sep 10;147(36):32447-32457. (PMID: 40728027)
Nat Rev Clin Oncol. 2023 Feb;20(2):116-134. (PMID: 36604531)
Adv Sci (Weinh). 2024 Apr;11(14):e2308659. (PMID: 38282076)
J Infect Dis. 2009 Nov 15;200(10):1623-6. (PMID: 19827944)
Arthritis Rheum. 2012 Sep;64(9):2953-63. (PMID: 22549634)
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5243-E5249. (PMID: 29760065)
J Lipid Res. 2024 Nov;65(11):100658. (PMID: 39332526)
PLoS One. 2012;7(5):e37275. (PMID: 22624006)
Exp Dermatol. 2014 Aug;23(8):585-90. (PMID: 24961936)
J Cell Physiol. 2009 Jul;220(1):196-203. (PMID: 19288477)
Int J Mol Sci. 2023 Dec 17;24(24):. (PMID: 38139402)
Biomaterials. 2025 Mar;314:122883. (PMID: 39405827)
Int J Hyperthermia. 2002 Nov-Dec;18(6):552-62. (PMID: 12537754)
Cancer Immunol Res. 2013 Oct;1(4):210-6. (PMID: 24490177)
Ned Tijdschr Geneeskd. 2016;160:A9852. (PMID: 27165455)
Chem Rev. 2024 Jan 24;124(2):455-553. (PMID: 38174868)
Immunity. 2001 Mar;14(3):303-13. (PMID: 11290339)
Int J Mol Sci. 2020 Nov 28;21(23):. (PMID: 33260615)
Cell. 2024 Dec 26;187(26):7470-7491.e32. (PMID: 39504957)
Front Med (Lausanne). 2023 Sep 15;10:1230854. (PMID: 37780563)
Int J Hyperthermia. 2012;28(1):9-18. (PMID: 22235780)
Clin Cancer Res. 2012 Oct 1;18(19):5449-59. (PMID: 22847809)
Arch Intern Med. 1998 Sep 28;158(17):1870-81. (PMID: 9759682)
Proc Biol Sci. 2014 Jan 22;281(1778):20132570. (PMID: 24452021)
J Cell Physiol. 1997 Mar;170(3):235-40. (PMID: 9066779)
ACS Nano. 2025 Feb 25;19(7):7213-7230. (PMID: 39928515)
Postgrad Med J. 2003 Dec;79(938):672-80. (PMID: 14707241)
Small. 2020 Nov;16(45):e2003969. (PMID: 33053265)
Life Sci. 2007 Jan 2;80(4):307-13. (PMID: 17084417)
J Am Chem Soc. 2021 Jun 2;143(21):8116-8128. (PMID: 33928777)
Biomedicines. 2023 Feb 03;11(2):. (PMID: 36830980)
Immunity. 2019 Jan 15;50(1):137-151.e6. (PMID: 30650373)
Nat Commun. 2022 May 19;13(1):2794. (PMID: 35589680)
J Chronic Dis. 1987;40(10):967-76. (PMID: 3038944)
Int J Dermatol. 1999 Aug;38(8):633-7. (PMID: 10487458)
Elife. 2023 Mar 14;12:. (PMID: 36917159)
J Comp Neurol. 2000 Dec 4;428(1):5-20. (PMID: 11058221)
ACS Nano. 2023 Oct 24;17(20):20218-20236. (PMID: 37838975)
Front Immunol. 2023 Oct 02;14:1257422. (PMID: 37849757)
J Endotoxin Res. 2004;10(1):39-53. (PMID: 15025823)
Sci Adv. 2021 Jun 9;7(24):. (PMID: 34108220)
Br J Cancer. 2005 Feb 14;92(3):421-5. (PMID: 15700041)
Eur Neurol. 2017;78(1-2):56-62. (PMID: 28633136)
Cancer Res. 2011 Jun 1;71(11):3872-80. (PMID: 21512134)
J Biol Chem. 2002 Feb 15;277(7):4981-8. (PMID: 11734555)
J Control Release. 2024 Aug;372:751-777. (PMID: 38909701)
Nat Rev Drug Discov. 2022 Jul;21(7):529-540. (PMID: 35701637)
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. (PMID: 31116675)
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2042-2047. (PMID: 28053227)
Blood. 2011 Jun 9;117(23):6172-83. (PMID: 21474672)
Int J Mol Sci. 2022 Nov 09;23(22):. (PMID: 36430282)
J Intensive Care. 2025 Jan 13;13(1):4. (PMID: 39806520)
Glob Adv Health Med. 2012 Mar;1(1):92-100. (PMID: 24278806)
Psychiatriki. 2013 Jul-Sep;24(3):208-12. (PMID: 24185088)
Cancer Lett. 2008 Nov 28;271(2):191-204. (PMID: 18597930)
Adv Sci (Weinh). 2026 Jan;13(1):e13566. (PMID: 41298282)
Ann Oncol. 2000 Oct;11(10):1229-39. (PMID: 11106110)
Zhonghua Xue Ye Xue Za Zhi. 2018 Jun 14;39(6):441-447. (PMID: 30032557)
Signal Transduct Target Ther. 2020 Sep 21;5(1):209. (PMID: 32958760)
Cancer Immunol Immunother. 2015 Mar;64(3):349-55. (PMID: 25445814)
Nat Rev Immunol. 2019 Mar;19(3):139. (PMID: 30728475)
Endocrinology. 2023 Aug 1;164(9):. (PMID: 37486737)
Chem Rev. 2023 Jun 14;123(11):6891-6952. (PMID: 37133878)
Signal Transduct Target Ther. 2025 Apr 02;10(1):115. (PMID: 40169560)
Blood. 2012 Sep 27;120(13):2600-9. (PMID: 22806894)
Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469)
Biomaterials. 2016 Jan;74:144-54. (PMID: 26454052)
Adv Mater. 2017 Feb;29(6):. (PMID: 27921316)
Front Immunol. 2024 Mar 12;15:1364128. (PMID: 38533499)
Am J Physiol Regul Integr Comp Physiol. 2006 May;290(5):R1262-70. (PMID: 16410400)
J Biomed Biotechnol. 2011;2011:367846. (PMID: 21687549)
Cancer Control. 2017 Apr;24(2):193-197. (PMID: 28441374)
Science. 1975 Apr 11;188(4184):166-8. (PMID: 1114347)
Acta Physiol (Oxf). 2024 Sep;240(9):e14187. (PMID: 38864370)
Crit Care Med. 2019 May;47(5):691-699. (PMID: 30789402)
Front Immunol. 2023 Oct 06;14:1258786. (PMID: 37869003)
Nat Rev Immunol. 2015 Jun;15(6):335-49. (PMID: 25976513)
Cancer Immunol Immunother. 2001 Oct;50(8):391-6. (PMID: 11726133)
Science. 2025 Jun 19;388(6753):eadx0043. (PMID: 40536983)
Br J Anaesth. 2012 Nov;109(5):754-61. (PMID: 22855633)
Compr Physiol. 2014 Oct;4(4):1563-604. (PMID: 25428854)
Nat Immunol. 2024 Oct;25(10):1820-1829. (PMID: 39112631)
Biomaterials. 2017 May;126:39-48. (PMID: 28254692)
Nat Commun. 2016 Oct 21;7:13193. (PMID: 27767031)
Adv Mater. 2021 Jan;33(4):e2004788. (PMID: 33289219)
J Immunol. 2009 Jul 15;183(2):890-6. (PMID: 19561102)
Adv Mater. 2023 Mar;35(10):e2209910. (PMID: 36576344)
Discov Immunol. 2024 Jan 30;3(1):kyae001. (PMID: 38567294)
Adv Mater. 2024 Oct;36(40):e2408511. (PMID: 39180264)
Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1316-26. (PMID: 16809483)
Integr Cancer Ther. 2017 Dec;16(4):479-484. (PMID: 27387685)
Adv Sci (Weinh). 2024 Jul;11(26):e2403858. (PMID: 38704691)
Nat Med. 2021 Jan;27(1):34-44. (PMID: 33442008)
Neuroimmunomodulation. 2001;9(2):55-64. (PMID: 11549887)
Chem Soc Rev. 2018 Apr 3;47(7):2280-2297. (PMID: 29528360)
Med Hist. 1990 Jul;34(3):294-310. (PMID: 2214949)
Front Neurosci. 2024 Oct 31;18:1397300. (PMID: 39544908)
Front Endocrinol (Lausanne). 2012 Jan 24;3(5):. (PMID: 22389645)
Theranostics. 2020 Feb 19;10(8):3793-3815. (PMID: 32206123)
Exp Mol Pathol. 1991 Oct;55(2):119-34. (PMID: 1657630)
Int J Oncol. 2010 Apr;36(4):899-904. (PMID: 20198334)
Biochem Biophys Res Commun. 2013 Sep 13;439(1):6-11. (PMID: 23973710)
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1111-F1121. (PMID: 31390229)
Compr Physiol. 2014 Jan;4(1):109-48. (PMID: 24692136)
Evol Med Public Health. 2020 Nov 23;9(1):26-35. (PMID: 33738101)
Nat Rev Immunol. 2002 Mar;2(3):185-94. (PMID: 11913069)
Science. 2022 Nov 25;378(6622):858-864. (PMID: 36423303)
Crit Care. 2024 Nov 13;28(1):367. (PMID: 39538310)
Adv Mater. 2019 Jun;31(23):e1900192. (PMID: 30916367)
Pharmacol Ther. 1994;64(3):529-64. (PMID: 7724661)
Neuron. 2018 Apr 4;98(1):31-48. (PMID: 29621489)
Int J Nanomedicine. 2020 Nov 19;15:9159-9180. (PMID: 33244232)
ACS Nano. 2023 Oct 10;17(19):19242-19253. (PMID: 37781935)
Chem Soc Rev. 2019 Apr 1;48(7):2053-2108. (PMID: 30259015)
DNA Cell Biol. 2023 Mar;42(3):107-112. (PMID: 36720071)
Nat Commun. 2016 Feb 04;7:10437. (PMID: 26842674)
Open Forum Infect Dis. 2020 May 02;7(5):ofaa132. (PMID: 32462043)
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66. (PMID: 11602373)
Adv Sci (Weinh). 2025 Jun;12(22):e2417625. (PMID: 40279550)
Adv Sci (Weinh). 2019 Sep 12;6(22):1901690. (PMID: 31763151)
Small. 2021 Apr;17(14):e2005241. (PMID: 33734595)
Biomedicines. 2024 Sep 23;12(9):. (PMID: 39335671)
Nano Lett. 2019 Aug 14;19(8):5277-5286. (PMID: 31331173)
J Leukoc Biol. 2011 Nov;90(5):951-62. (PMID: 21873456)
J Am Chem Soc. 2018 Feb 14;140(6):2165-2178. (PMID: 29376345)
J Physiol. 2024 May;602(10):2227-2251. (PMID: 38690610)
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22357-22366. (PMID: 32839313)
Int J Nanomedicine. 2024 Apr 29;19:3827-3846. (PMID: 38708180)
J Lipid Res. 2024 Sep;65(9):100617. (PMID: 39128824)
Adv Mater. 2023 Nov;35(48):e2303149. (PMID: 37691545)
Front Cell Dev Biol. 2023 May 25;11:1186050. (PMID: 37305674)
Small Methods. 2023 May;7(5):e2300354. (PMID: 37191336)
Chest. 2004 Nov;126(5):1645-55. (PMID: 15539739)
J Leukoc Biol. 2007 Nov;82(5):1322-31. (PMID: 17711975)
J Immunol. 1998 Jan 15;160(2):961-9. (PMID: 9551935)
Sci Rep. 2021 Mar 22;11(1):6531. (PMID: 33753764)
Am J Med Sci. 2024 Aug;368(2):85-89. (PMID: 38795968)
EMBO Mol Med. 2012 Jul;4(7):617-32. (PMID: 22367739)
Anticancer Res. 2004 Sep-Oct;24(5C):3295-301. (PMID: 15515424)
Int J Hyperthermia. 2013 Aug;29(5):423-35. (PMID: 23863046)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
Neuroscientist. 2018 Aug;24(4):381-399. (PMID: 29557255)
Pediatr Blood Cancer. 2005 Jun 15;44(7):679-81. (PMID: 15700247)
Blood. 2001 May 1;97(9):2727-33. (PMID: 11313264)
J Neurooncol. 2006 May;78(1):7-14. (PMID: 16314937)
J Leukoc Biol. 2007 May;81(5):1179-87. (PMID: 17311933)
Cancer Immunol Immunother. 2002 Dec;51(11-12):603-13. (PMID: 12439605)
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2408969121. (PMID: 39680767)
Nat Commun. 2021 Feb 2;12(1):742. (PMID: 33531498)
Crit Care. 2011;15(3):222. (PMID: 21672276)
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. (PMID: 33608497)
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):. (PMID: 34161266)
Compr Physiol. 2013 Apr;3(2):785-97. (PMID: 23720329)
Metabolites. 2023 Mar 22;13(3):. (PMID: 36984901)
Semin Cancer Biol. 2022 Dec;87:17-31. (PMID: 36354098)
Nucleic Acids Res. 2016 Apr 7;44(6):2888-97. (PMID: 26825461)
Nat Commun. 2019 Oct 25;10(1):4871. (PMID: 31653838)
Clin Transl Med. 2023 May;13(5):e1256. (PMID: 37218972)
Annu Rev Pathol. 2018 Jan 24;13:395-412. (PMID: 29414248)
Res Microbiol. 1994 May;145(4):269-72. (PMID: 7997640)
Nat Rev Neurosci. 2003 Jul;4(7):529-39. (PMID: 12838328)
Cell Mol Immunol. 2016 May;13(3):316-27. (PMID: 26908374)
Cancer Cell. 2021 Sep 13;39(9):1167-1168. (PMID: 34388378)
World J Clin Cases. 2021 Jan 16;9(2):296-307. (PMID: 33521098)
Lancet. 1982 May 8;1(8280):1079-80. (PMID: 6122886)
Immunol Lett. 2005 Apr 15;98(1):153-9. (PMID: 15790521)
Transl Oncol. 2018 Apr;11(2):330-337. (PMID: 29425952)
Small. 2019 Mar;15(13):e1900205. (PMID: 30828968)
Kidney Res Clin Pract. 2015 Dec;34(4):194-200. (PMID: 26779421)
Nature. 2022 Jun;606(7916):937-944. (PMID: 35676482)
J Comp Neurol. 2004 Apr 19;472(1):113-29. (PMID: 15024756)
Pharmacol Ther. 2006 Jul;111(1):194-223. (PMID: 16460809)
Immunity. 2020 Feb 18;52(2):328-341.e5. (PMID: 32049050)
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1865-70. (PMID: 15684048)
Adv Sci (Weinh). 2020 Jul 17;7(17):2000863. (PMID: 32995121)
Sci Immunol. 2024 Sep 20;9(99):eadp3475. (PMID: 39303018)
Endocrinology. 2012 Oct;153(10):4849-61. (PMID: 22872578)
J Immunol. 2005 Mar 15;174(6):3676-85. (PMID: 15749906)
Biomark Res. 2023 Mar 9;11(1):28. (PMID: 36890557)
Clin Cancer Res. 2001 Jan;7(1):215-9. (PMID: 11205912)
J Neurosci. 2017 May 10;37(19):5035-5044. (PMID: 28438967)
Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):245-256. (PMID: 38769827)
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R332-R339. (PMID: 15802558)
J Control Release. 2015 Apr 28;204:85-97. (PMID: 25744825)
Adv Sci (Weinh). 2025 Jan;12(2):e2406328. (PMID: 39574346)
Small. 2024 Feb;20(7):e2305426. (PMID: 37803412)
Nat Rev Drug Discov. 2022 Jan;21(1):41-59. (PMID: 34526696)
Intractable Rare Dis Res. 2016 May;5(2):97-102. (PMID: 27195192)
Neurology. 1997 Mar;48(3):768-73. (PMID: 9065563)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Nat Commun. 2023 Nov 4;14(1):7107. (PMID: 37925510)
Signal Transduct Target Ther. 2021 Feb 26;6(1):94. (PMID: 33637672)
ACS Nano. 2025 Apr 08;19(13):12982-12995. (PMID: 40138545)
N Engl J Med. 2020 Dec 3;383(23):2255-2273. (PMID: 33264547)
Adv Sci (Weinh). 2018 Mar 25;5(6):1700805. (PMID: 29938166)
Adv Mater. 2014 Dec 23;26(48):8154-62. (PMID: 25331930)
Acta Oncol. 2013 Feb;52(2):455-7. (PMID: 22934556)
Nat Neurosci. 2007 Sep;10(9):1131-3. (PMID: 17676060)
Int J Mol Sci. 2024 Apr 10;25(8):. (PMID: 38673794)
J Immunol. 2009 Jun 15;182(12):7451-8. (PMID: 19494268)
Ann N Y Acad Sci. 1998 Sep 29;856:224-233. (PMID: 9917881)
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2030-2037. (PMID: 36084325)
J Am Chem Soc. 2025 Sep 10;147(36):32447-32457. (PMID: 40728027)
Nat Rev Clin Oncol. 2023 Feb;20(2):116-134. (PMID: 36604531)
Adv Sci (Weinh). 2024 Apr;11(14):e2308659. (PMID: 38282076)
J Infect Dis. 2009 Nov 15;200(10):1623-6. (PMID: 19827944)
Arthritis Rheum. 2012 Sep;64(9):2953-63. (PMID: 22549634)
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5243-E5249. (PMID: 29760065)
J Lipid Res. 2024 Nov;65(11):100658. (PMID: 39332526)
PLoS One. 2012;7(5):e37275. (PMID: 22624006)
Exp Dermatol. 2014 Aug;23(8):585-90. (PMID: 24961936)
J Cell Physiol. 2009 Jul;220(1):196-203. (PMID: 19288477)
Int J Mol Sci. 2023 Dec 17;24(24):. (PMID: 38139402)
Biomaterials. 2025 Mar;314:122883. (PMID: 39405827)
Int J Hyperthermia. 2002 Nov-Dec;18(6):552-62. (PMID: 12537754)
Cancer Immunol Res. 2013 Oct;1(4):210-6. (PMID: 24490177)
Ned Tijdschr Geneeskd. 2016;160:A9852. (PMID: 27165455)
Chem Rev. 2024 Jan 24;124(2):455-553. (PMID: 38174868)
Immunity. 2001 Mar;14(3):303-13. (PMID: 11290339)
Int J Mol Sci. 2020 Nov 28;21(23):. (PMID: 33260615)
Cell. 2024 Dec 26;187(26):7470-7491.e32. (PMID: 39504957)
Front Med (Lausanne). 2023 Sep 15;10:1230854. (PMID: 37780563)
Int J Hyperthermia. 2012;28(1):9-18. (PMID: 22235780)
Clin Cancer Res. 2012 Oct 1;18(19):5449-59. (PMID: 22847809)
Arch Intern Med. 1998 Sep 28;158(17):1870-81. (PMID: 9759682)
Proc Biol Sci. 2014 Jan 22;281(1778):20132570. (PMID: 24452021)
J Cell Physiol. 1997 Mar;170(3):235-40. (PMID: 9066779)
ACS Nano. 2025 Feb 25;19(7):7213-7230. (PMID: 39928515)
Postgrad Med J. 2003 Dec;79(938):672-80. (PMID: 14707241)
Small. 2020 Nov;16(45):e2003969. (PMID: 33053265)
Life Sci. 2007 Jan 2;80(4):307-13. (PMID: 17084417)
J Am Chem Soc. 2021 Jun 2;143(21):8116-8128. (PMID: 33928777)
Biomedicines. 2023 Feb 03;11(2):. (PMID: 36830980)
Immunity. 2019 Jan 15;50(1):137-151.e6. (PMID: 30650373)
Nat Commun. 2022 May 19;13(1):2794. (PMID: 35589680)
J Chronic Dis. 1987;40(10):967-76. (PMID: 3038944)
Int J Dermatol. 1999 Aug;38(8):633-7. (PMID: 10487458)
Elife. 2023 Mar 14;12:. (PMID: 36917159)
J Comp Neurol. 2000 Dec 4;428(1):5-20. (PMID: 11058221)
ACS Nano. 2023 Oct 24;17(20):20218-20236. (PMID: 37838975)
Front Immunol. 2023 Oct 02;14:1257422. (PMID: 37849757)
J Endotoxin Res. 2004;10(1):39-53. (PMID: 15025823)
Sci Adv. 2021 Jun 9;7(24):. (PMID: 34108220)
Br J Cancer. 2005 Feb 14;92(3):421-5. (PMID: 15700041)
Eur Neurol. 2017;78(1-2):56-62. (PMID: 28633136)
Cancer Res. 2011 Jun 1;71(11):3872-80. (PMID: 21512134)
J Biol Chem. 2002 Feb 15;277(7):4981-8. (PMID: 11734555)
J Control Release. 2024 Aug;372:751-777. (PMID: 38909701)
Nat Rev Drug Discov. 2022 Jul;21(7):529-540. (PMID: 35701637)
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. (PMID: 31116675)
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2042-2047. (PMID: 28053227)
Blood. 2011 Jun 9;117(23):6172-83. (PMID: 21474672)
Int J Mol Sci. 2022 Nov 09;23(22):. (PMID: 36430282)
J Intensive Care. 2025 Jan 13;13(1):4. (PMID: 39806520)
Glob Adv Health Med. 2012 Mar;1(1):92-100. (PMID: 24278806)
Psychiatriki. 2013 Jul-Sep;24(3):208-12. (PMID: 24185088)
Cancer Lett. 2008 Nov 28;271(2):191-204. (PMID: 18597930)
Adv Sci (Weinh). 2026 Jan;13(1):e13566. (PMID: 41298282)
Ann Oncol. 2000 Oct;11(10):1229-39. (PMID: 11106110)
Zhonghua Xue Ye Xue Za Zhi. 2018 Jun 14;39(6):441-447. (PMID: 30032557)
Signal Transduct Target Ther. 2020 Sep 21;5(1):209. (PMID: 32958760)
Cancer Immunol Immunother. 2015 Mar;64(3):349-55. (PMID: 25445814)
Nat Rev Immunol. 2019 Mar;19(3):139. (PMID: 30728475)
Endocrinology. 2023 Aug 1;164(9):. (PMID: 37486737)
Chem Rev. 2023 Jun 14;123(11):6891-6952. (PMID: 37133878)
Signal Transduct Target Ther. 2025 Apr 02;10(1):115. (PMID: 40169560)
Blood. 2012 Sep 27;120(13):2600-9. (PMID: 22806894)
Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469)
Biomaterials. 2016 Jan;74:144-54. (PMID: 26454052)
Adv Mater. 2017 Feb;29(6):. (PMID: 27921316)
Front Immunol. 2024 Mar 12;15:1364128. (PMID: 38533499)
Am J Physiol Regul Integr Comp Physiol. 2006 May;290(5):R1262-70. (PMID: 16410400)
J Biomed Biotechnol. 2011;2011:367846. (PMID: 21687549)
Cancer Control. 2017 Apr;24(2):193-197. (PMID: 28441374)
Science. 1975 Apr 11;188(4184):166-8. (PMID: 1114347)
Acta Physiol (Oxf). 2024 Sep;240(9):e14187. (PMID: 38864370)
Crit Care Med. 2019 May;47(5):691-699. (PMID: 30789402)
Front Immunol. 2023 Oct 06;14:1258786. (PMID: 37869003)
Nat Rev Immunol. 2015 Jun;15(6):335-49. (PMID: 25976513)
Cancer Immunol Immunother. 2001 Oct;50(8):391-6. (PMID: 11726133)
Science. 2025 Jun 19;388(6753):eadx0043. (PMID: 40536983)
Br J Anaesth. 2012 Nov;109(5):754-61. (PMID: 22855633)
Compr Physiol. 2014 Oct;4(4):1563-604. (PMID: 25428854)
Nat Immunol. 2024 Oct;25(10):1820-1829. (PMID: 39112631)
Biomaterials. 2017 May;126:39-48. (PMID: 28254692)
Nat Commun. 2016 Oct 21;7:13193. (PMID: 27767031)
Adv Mater. 2021 Jan;33(4):e2004788. (PMID: 33289219)
J Immunol. 2009 Jul 15;183(2):890-6. (PMID: 19561102)
Adv Mater. 2023 Mar;35(10):e2209910. (PMID: 36576344)
Discov Immunol. 2024 Jan 30;3(1):kyae001. (PMID: 38567294)
Adv Mater. 2024 Oct;36(40):e2408511. (PMID: 39180264)
Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1316-26. (PMID: 16809483)
Integr Cancer Ther. 2017 Dec;16(4):479-484. (PMID: 27387685)
Adv Sci (Weinh). 2024 Jul;11(26):e2403858. (PMID: 38704691)
Nat Med. 2021 Jan;27(1):34-44. (PMID: 33442008)
Neuroimmunomodulation. 2001;9(2):55-64. (PMID: 11549887)
Chem Soc Rev. 2018 Apr 3;47(7):2280-2297. (PMID: 29528360)
Med Hist. 1990 Jul;34(3):294-310. (PMID: 2214949)
Front Neurosci. 2024 Oct 31;18:1397300. (PMID: 39544908)
Front Endocrinol (Lausanne). 2012 Jan 24;3(5):. (PMID: 22389645)
Theranostics. 2020 Feb 19;10(8):3793-3815. (PMID: 32206123)
Exp Mol Pathol. 1991 Oct;55(2):119-34. (PMID: 1657630)
Int J Oncol. 2010 Apr;36(4):899-904. (PMID: 20198334)
Biochem Biophys Res Commun. 2013 Sep 13;439(1):6-11. (PMID: 23973710)
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1111-F1121. (PMID: 31390229)
Compr Physiol. 2014 Jan;4(1):109-48. (PMID: 24692136)
Evol Med Public Health. 2020 Nov 23;9(1):26-35. (PMID: 33738101)
Nat Rev Immunol. 2002 Mar;2(3):185-94. (PMID: 11913069)
Science. 2022 Nov 25;378(6622):858-864. (PMID: 36423303)
Crit Care. 2024 Nov 13;28(1):367. (PMID: 39538310)
Adv Mater. 2019 Jun;31(23):e1900192. (PMID: 30916367)
Pharmacol Ther. 1994;64(3):529-64. (PMID: 7724661)
Neuron. 2018 Apr 4;98(1):31-48. (PMID: 29621489)
Int J Nanomedicine. 2020 Nov 19;15:9159-9180. (PMID: 33244232)
Grant Information:
32271387 National Natural Science Foundation of China; 2021ZD0202003 Sci-Tech Innovation 2030 Major Project of Brain Science and brain-inspired intelligence technology; 2022XD052 Talent Program of Shanghai Municipal Health Commission; 23ZR1465200 Natural Science Foundation of Shanghai; 24ZR1468900 Natural Science Foundation of Shanghai
Contributed Indexing:
Keywords: engineered fever therapy; fevers; nanomaterials; thermal immunotherapy
Entry Date(s):
Date Created: 20251126 Date Completed: 20260105 Latest Revision: 20260107
Update Code:
20260107
PubMed Central ID:
PMC12767105
DOI:
10.1002/advs.202513566
PMID:
41298282
Database:
MEDLINE
Weitere Informationen
Fever, a conserved physiological response, orchestrates robust immunomodulation with significant therapeutic potential. Engineered fever therapy (EFT) leverages this mechanism to activate systemic immune response, emerging as a transformative adjuvant strategy for disease management, particularly in oncology. However, achieving precise and safe EFT remains challenging, largely due to unpredictable temperature fluctuations and inconsistent immune responses. To address these limitations, thermal immunotherapy integrates precision thermal modulation with nanotechnology, enabling targeted induction of fever-range temperatures (38.5-40 °C) within tumor sites. Building upon physiological fever mechanisms and precision bioengineering, controllable EFT establishes a new paradigm with three core principles: i) precise fever induction with input and process control, ii) quantitative reprogramming of immune pathways, and iii) enhanced safety through optimized fever dynamics. This review comprehensively summarizes the molecular and physiological underpinnings of fever, evaluates its therapeutic potential in disease management, and presents recent progress in thermal immunotherapy and the EFT. Furthermore, future perspectives for controllable EFT are discussed and critically assessed, along with its opportunities and main challenges for clinical translation in precision oncology.
(© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH.)